OncoSec Appoints Daniel J. O'Connor as Chief Executive Officer to Lead Next Stage of Growth as a Fully Integrated Late Stage Development and Commercial Company Nov 7, 2017
OncoSec Closes $7.1 Million Registered Direct Offering Priced At-the-Market and Announces $1.1 Million Registered Direct Offering Priced Above Market Oct 25, 2017
OncoSec Presents Positive Phase 2 Data for ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non-Responder Melanoma Patients Oct 19, 2017
OncoSec to Host Fourth Quarter and Year End Financial Results Conference Call on October 25, 2017 Oct 13, 2017
OncoSec to Present Updated Clinical and Immune Biomarker Data from its Monotherapy and Combination Therapy Studies with ImmunoPulse® IL-12 at the 9th World Congress of Melanoma - A Joint Meeting with the Society for Melanoma Research Oct 12, 2017
OncoSec Announces Acceptance of Late Breaking Abstract at Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017 Oct 11, 2017
OncoSec Initiates Registration Directed Clinical Trial, KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Merck's KEYTRUDA® (pembrolizumab) Oct 10, 2017
OncoSec Presents Clinical Overview of Comprehensive Immune Monitoring Data Demonstrating Conversion of "Cold" Tumors to "Hot" Tumors with ImmunoPulse® IL-12 and Pembrolizumab Combination Therapy Sep 27, 2017
